Feb 13 (Reuters) - Bio Path Holdings BPTH.O:
BIO-PATH HOLDINGS PROVIDES KEY CLINICAL UPDATES
BIO PATH HOLDINGS: REPORTS CONTINUED PATIENT PROGRESS FROM PHASE 2 TRIPLE COMBINATION STUDY OF PREXIGEBERSEN IN ACUTE MYELOID LEUKEMIA (AML)
Source text: ID:nGNX3SPmN1
Further company coverage: BPTH.O